Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1

Cancer Science

Volumn 99, Issue 5, 2008, Pages 1000-1007

  Ohno, Yoshiya ^a   Suda, Kentaro ^a   Masuko, Kazue ^a   Yagi, Hideki ^a   Hashimoto, Yoshiyuki ^b   Masuko, Takashi ^a  

^a KINKI UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; CD98 ANTIGEN; COMPLEMENTARY DNA; CYSTEINE; DISULFIDE; GREEN FLUORESCENT PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SOL22; MONOCLONAL ANTIBODY SOL69; RECOMBINANT PROTEIN; CANCER ANTIBODY; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CLONE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; EXTRACELLULAR SPACE; FEMALE; GENETIC TRANSFECTION; HELA CELL; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDOMA CELL CULTURE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; SPLEEN CELL; TUMOR CELL LINE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DOWN REGULATION; FISCHER 344 RAT; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

EID: 43649099259     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00770.x     Document Type: Article

References (45)

1. Broer S, Broer A, Hamprecht B. The 4F2hc surface antigen is necessary for expression of system 1-like neutral amino acid-transport activity in C6-BU-1 rat glioma cells: Evidence from expression studies in Xenopus laevis oocytes. Biochem J 1995; 312: 863-70.
2. Haynes BF, Hemler ME, Mann DL et al. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 1981; 126: 1409-14.
3. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23.629-32.
4. Masuko T, Abe J, Yagita H, Hashimoto Y. Human bladder cancer cell-surface antigens recognized by murine monoclonal antibodies raised against T24 bladder cancer cells. Jpn J Cancer Res 1985; 76: 386-94.
5. Yagita H, Masuko T, Hashimoto Y. Inhibition of tumor cell growth in vitro by murine monoclonal antibodies that recognize a proliferation-associated cell surface antigen system in rats and humans. Cancer Res 1986; 46: 1478-84.
6. Yagita H, Masuko T, Takahashi N, Hashimoto Y. Monoclonal antibodies that inhibit activation and proliferation of lymphocytes. I. Expression of the antigen on monocytes and activated lymphocytes. J Immunol 1986; 136: 2055-61.
7. Hara K, Kudoh H, Enomoto T, Hashimoto Y, Masuko T. Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98. Biochem Biophys Res Commun 1999; 262: 720-5.
8. Hara K, Kudoh H, Enomoto T, Hashimoto Y, Masuko T. Enhanced tumorigenicity caused by truncation of the extracellular domain of GP125/ CD98 heavy chain. Oncogene 2000; 19: 6209-15.
9. Shishido T, Uno S, Kamohara M et al. Transformation of BALB3T3 cells caused by over-expression of rat CD98 heavy chain (HC) requires its association with light chain: Mis-sense mutation in a cysteine residue of CD98HC eliminates its transforming activity. Int J Cancer 2000; 87: 311-16.
10. Mastroberardino L, Spindler B, Pfeiffer R et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 1998; 395: 288-91.
11. Ohgimoto S, Tabata N, Suga S et al. Molecular characterization of fusion regulatory protein-1 (FRP-1) that induces multinucleated giant cell formation of monocytes and HIV gp160-mediated cell fusion. FRP-1 and 4F2/ CD98 are identical molecules. J Immunol 1995; 155: 3585-92.
12. Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997; 390: 81-5.
13. Warren AP, Patel K, McConkey DJ, Palacios R. CD98: A type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells. Blood 1996; 87: 3676-87.
14. Nakamura E, Sato M, Yang H et al. 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer. J Biol Chem 1999; 274: 3009-16.
15. + -independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem 1999; 274: 19.745-51.
16. Pineda M, Fernandez E, Torrents D et al. Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an l-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 1999; 274: 19.738-44.
17. Rossier G, Meier C, Bauch C et al. LAT2, a new basolateral 4F2hc/ CD98-associated amino acid transporter of kidney and intestine. J Biol Chem 1999; 274: 34.948-54.
18. +L: A candidate gene for lysinuric protein intolerance. J Biol Chem 1998; 273: 32.437-45.
19. + L-type by heterodimers of 4F2hc/CD98 and members of the glycoprotein-associated amino acid transporter family. EMBO J 1999; 18: 49-57.
20. +-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral d- and l-amino acids. J Biol Chem 2000; 275: 9690-8.
21. Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 1999; 274: 11.455-8.
22. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990; 70: 43-77.
23. Grudzinski W, Matula M, Sielewiesiuk J, Kernen P, Krupa Z, Gruszecki WI. Effect of 13-cis violaxanthin on organization of light harvesting complex II in monomolecular layers. Biochim Biophys Acta 2001; 1503: 291-302.
24. Sang J, Lim YP, Panzica M, Finch P, Thompson NL. TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation. Cancer Res 1995; 55: 1152-9.
25. Wolf DA, Wang S, Panzica MA, Bassily NH, Thompson NL. Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: Homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 1996; 56: 5012-22.
26. Yanagida O, Kanai Y, Chairoungdua A et al. Human l-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: 291-302.
27. Gibbs RA, Weinstock GM, Metzker ML et al. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004; 428: 493-521.
28. Yoon JH, Kim IJ, Kim H et al. Amino acid transport system L is differently expressed in human normal oral keratinocytes and human oral cancer cells. Cancer Lett 2005; 222: 237-45.
29. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-30.
30. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-9.
31. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
32. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
33. Tokuda Y, Watanabe T, Omuro Y et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer. Br J Cancer 1999; 81: 1419-25.
34. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
35. Tokuda Y, Ohnishi Y, Shimamura K et al. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 1996; 73: 1362-5.
36. Tokuda Y, Okumura A, Ohta M et al. A humanized anti-c-erbB-2 monoclonal antibody for the treatment of breast cancer. Breast Cancer 1997; 4: 269-72.
37. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
38. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
39. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
40. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711-16.
41. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-74.
42. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-66.
43. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
44. Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998; 9: 527-34.
45. Wilson WH. Chemotherapy sensitization by rituximab: Experimental and clinical evidence. Semin Oncol 2000; 27: 30-6.